1.
|
9 p, 975.2 KB |
Association between control group therapy and magnitude of clinical benefit of cancer drugs
/
Molto, Consolacion (Princess Margaret Cancer Centre and University of Toronto. Division of Medical Oncology and Hematology, Department of Medicine) ;
Tibau Martorell, Ariadna (Institut d'Investigació Biomèdica Sant Pau) ;
Bujosa, Aida (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Tapia, Jose Carlos (Institut d'Investigació Biomèdica Sant Pau) ;
Mittal, Abhenil (Princess Margaret Cancer Centre and University of Toronto. Division of Medical Oncology and Hematology, Department of Medicine) ;
Tamimi, Faris (Princess Margaret Cancer Centre and University of Toronto. Division of Medical Oncology and Hematology, Department of Medicine) ;
Amir, Eitan (Princess Margaret Cancer Centre and University of Toronto. Division of Medical Oncology and Hematology, Department of Medicine) ;
Universitat Autònoma de Barcelona
Little is known about the impact of control group therapy on clinical benefit scales such as American Society of Clinical Oncology Value Framework (ASCO-VF), European Society for Medical Oncology Magnitude Clinical Benefit Scale (ESMO-MCBS), National Comprehensive Cancer Network (NCCN) Evidence Blocks and ASCO Cancer Research Committee (ASCO-CRC). [...]
2022 - 10.1038/s41598-022-25983-9
Scientific reports, Vol. 12 (december 2022)
|
|
2.
|
14 p, 2.0 MB |
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer : patient-reported outcomes from the FLIPPER trial
/
Tibau Martorell, Ariadna (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez, M. Teresa ;
Ramos, Manuel ;
de la Cruz Merino, Luis ;
Santaballa, Ana ;
O'Connor, Miriam ;
Martínez-Jañez, Noelia ;
Moreno, Fernando ;
Fernández, Isaura ;
Virizuela, Juan Antonio ;
Alarcón, Jesús ;
de la Haba Rodríguez, Juan Rafael ;
Sánchez-Rovira, Pedro ;
Albacar, Cinta Rosa ;
Bueno Muiño, Coralia ;
Kelly, Catherine ;
Casas, Maribel ;
Bezares, Susana ;
Rosell, Libertad ;
Albanell Mestres, Joan (Hospital del Mar (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2− advanced breast cancer (ABC). [...]
2023 - 10.1177/17588359221148921
Therapeutic Advances in Medical Oncology, Vol. 15 (january 2023)
|
|
3.
|
13 p, 1.7 MB |
Clinical benefit of cancer drugs approved in Switzerland 2010-2019
/
Adam, Roman (Faculty of Medicine. University of Basel) ;
Tibau Martorell, Ariadna (Institut d'Investigació Biomèdica Sant Pau) ;
Valiente, C.M. (Institut d'Investigació Biomèdica Sant Pau) ;
Šeruga, Bostjan (Univerza V Ljubljani) ;
Ocaña, Alberto (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Amir, Eitan (University of Toronto, Canada) ;
Templeton, Arnoud (St. Clara Research Ltd.)
Background It is unknown to what extent cancer drugs approved in Switzerland by the Swissmedic fulfil criteria of clinical benefit according to the European Society of Medical Oncology Magnitude of Clinical Benefit Scale version 1. [...]
2022 - 10.1371/journal.pone.0268545
PloS one, Vol. 17 Núm. 6 June (june 2022) , p. e0268545
|
|
4.
|
|
5.
|
12 p, 430.7 KB |
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia
/
Hwang, Thomas J. (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Kesselheim, Aaron S. (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Tibau Martorell, Ariadna (Institut d'Investigació Biomèdica Sant Pau) ;
Lee, ChangWon C. (Brigham and Women's Hospital (Boston, Estats Units d'Amèrica)) ;
Vokinger, Kerstin N. (Institute of Law, University of Zurich, Zurich, Switzerland) ;
Universitat Autònoma de Barcelona
We studied all new cancer drugs approved in the six aforementioned jurisdictions from 2007 to 2020. We extracted all applicable expedited programs, total regulatory review times, and, for drugs first approved by the FDA, times to subsequent regulatory approval. [...]
2022 - 10.1200/OP.21.00909
JCO Oncology Practice, Vol. 18 (june 2022) , p. e1522-e1532
|
|
6.
|
11 p, 290.2 KB |
Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations : A Systematic Review and Meta-Regression
/
Templeton, Arnoud (University Basel, Switzerland) ;
Gonzalez, Laura Diez (Complejo Hospitalario Universitario de Albacete) ;
Vera-Badillo, Francisco E. (Department of Oncology, Queen's University, Kingston Canada) ;
Tibau Martorell, Ariadna (Institut d'Investigació Biomèdica Sant Pau) ;
Goldstein, Robyn (University of Toronto, Canada) ;
Šeruga, Boštjan (Institute of Oncology, Ljubljana, Slovenia) ;
Srikanthan, Amirrtha (University of Toronto, Canada) ;
Pandiella, Atanasio (Universidad de Salamanca) ;
Amir, Eitan (University of Toronto, Canada) ;
Ocana, Alberto (Complejo Hospitalario Universitario de Albacete) ;
Universitat Autònoma de Barcelona
Germline mutations in the BRCA1 and BRCA2 genes are the most frequent known hereditary causes of familial breast cancer. Little is known about the interaction of age at diagnosis, estrogen receptor (ER) and progesterone receptor (PgR) expression and outcomes in patients with BRCA1 or BRCA2 mutations. [...]
2016 - 10.1371/journal.pone.0154789
PloS one, Vol. 11 (may 2016)
|
|
7.
|
10 p, 1.0 MB |
Electronic health records and patient registries in medical oncology departments in Spain
/
Ribelles, Nuria (Instituto de Investigación Biomédica de Málaga) ;
Alvarez-Lopez, Isabel (Biodonostia Osasun Ikerketako Institutura (País Basc)) ;
Arcusa, Àngels (Consorci Sanitari de Terrassa) ;
Chacón, José Ignacio (Hospital Virgen de la Salud (Toledo)) ;
de la Haba Rodríguez, Juan Rafael (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Garcia-Corbacho, Javier (Hospital Clínic i Provincial de Barcelona) ;
Garcia-Mata, Jesus (Complejo Hospitalario Universitario de Ourense) ;
Jara Sánchez, Carlos (Hospital Universitario Fundación Alcorcón) ;
Jerez, José Manuel (Universidad de Málaga) ;
Lázaro, Martín (Hospital Álvaro Cunqueiro (Vigo)) ;
Leon, Luis (Complejo Hospitalario Universitario de Santiago de Compostela) ;
Ramirez-Merino, Natalia (Oncología Médica, Hospital Universitario Infanta Elena (Madrid)) ;
Tibau Martorell, Ariadna (Institut d'Investigació Biomèdica Sant Pau) ;
Garcia Palomo, Andrés (Complejo Asistencial Universitario de León) ;
Universitat Autònoma de Barcelona
We aimed to evaluate the current situation of electronic health records (EHRs) and patient registries in the oncology departments of hospitals in Spain. This was a cross-sectional study conducted from December 2018 to September 2019. [...]
2021 - 10.1007/s12094-021-02614-9
Clinical & Translational Oncology, Vol. 23 (april 2021) , p. 2099-2108
|
|
8.
|
7 p, 951.5 KB |
Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer
/
Tibau Martorell, Ariadna (Institut d'Investigació Biomèdica Sant Pau) ;
Anguera, Georgia (Institut d'Investigació Biomèdica Sant Pau) ;
Andrés-Pretel, Fernando (Research Foundation of the Paraplegics Hospital of Toledo, Toledo, Spain) ;
Templeton, Arnoud (University of Basel, Basel, Switzerland) ;
Seruga, Bostjan (Institute of Oncology Ljubljana and University of Ljubljana, Ljubljana, Slovenia) ;
Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ;
Amir, Eitan (University of Toronto, Toronto, Ontario, Canada) ;
Ocana, Alberto (Complejo Hospitalario Universitario de Albacete) ;
Universitat Autònoma de Barcelona
Clinical research is conducted by academia, cooperative groups (CGs) or pharmaceutical industry. Here, we evaluate the role of CGs and funding sources in the development of guidelines for breast cancer therapies. [...]
2018 - 10.18632/oncotarget.24589
Oncotarget, Vol. 9 (february 2018) , p. 15061-15067
|
|
9.
|
7 p, 303.7 KB |
Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer
/
Tibau Martorell, Ariadna (Institut d'Investigació Biomèdica Sant Pau) ;
López Vilaró, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Pérez Olabarria, Maitane (Institut d'Investigació Biomèdica Sant Pau) ;
Vázquez, Tania (Institut d'Investigació Biomèdica Sant Pau) ;
Pons, Cristina (Institut d'Investigació Biomèdica Sant Pau) ;
Gich, Ignasi (Institut d'Investigació Biomèdica Sant Pau) ;
Alonso, Carmen (Institut d'Investigació Biomèdica Sant Pau) ;
Ojeda, Belén (Institut d'Investigació Biomèdica Sant Pau) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
Lerma Puertas, Enrique (Institut d'Investigació Biomèdica Sant Pau) ;
Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ;
Escuin i Borràs, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Human epidermal growth factor receptor 2 (HER2) and topoisomerase II alpha (TOP2A) genes have been proposed as predictive biomarkers of sensitivity to anthracycline chemotherapy. Recently, chromosome 17 centromere enumeration probe (CEP17) duplication has also been associated with increased responsiveness to anthracyclines. [...]
2014 - 10.1016/j.neo.2014.08.012
Neoplasia (New York, N.Y.), Vol. 16 (october 2014) , p. 861-867
|
|
10.
|
9 p, 234.9 KB |
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer : results from the GEICAM/2006-14 trial
/
Alba, Emilio (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Albanell Mestres, Joan (Parc de Salut MAR de Barcelona) ;
de la Haba Rodríguez, Juan Rafael (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ;
Calvo, L.. (Complejo Hospitalario Universitario de A Coruña) ;
Sánchez-Rovira, P. (Complejo Hospitalario de Jaén) ;
Ramos, M. (Centro Oncológico de Galicia) ;
Rojo, F. (Hospital Universitario Fundación Jiménez Díaz) ;
Burgués, Octavio (Hospital Clínic Universitari (València)) ;
Carrasco, E. (Grupo GEICAM de Investigación en Cáncer de Mama) ;
Caballero, Rosalía (Grupo GEICAM de Investigación en Cáncer de Mama) ;
Porras, I (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Tibau Martorell, Ariadna (Institut d'Investigació Biomèdica Sant Pau) ;
Cámara, M. C. (Grupo GEICAM de Investigación en Cáncer de Mama) ;
Lluch, Ana (Hospital Clínic Universitari (València)) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. [...]
2014 - 10.1038/bjc.2013.831
British Journal of Cancer, Vol. 110 (01 2014) , p. 1139-1147
|
|